TNFRSF11A and neoplasm: Denosumab inhibits osteoclast activation and promotes bone deposition, and its specificity and affinity for RANKL is higher than that of RANK, blocking the RANK/RANKL signaling pathway by binding to RANKL and thus inhibiting the interaction between neoplastic stromal cells and multinucleated giant cells, which is closely associated with tumor recurrence (10).